Cervomed Inc is a clinical stage company based in Boston, MA, focused on developing innovative treatments for degenerative diseases of the brain. Their approach involves intervening early in neurodegenerative diseases, such as Dementia with Lewy Bodies, Alzheimer's Disease, and Stroke Recovery, with the aim of reversing synaptic dysfunction responsible for disease symptoms and progression before nerve cell death occurs.
Through their development of ne amapimod, an oral, selective small molecule inhibitor of the protein kinase p38 alpha, Cervomed aims to target the key driver of synaptic dysfunction in neurodegenerative processes. Their research and clinical studies have shown promising results in reversing synaptic dysfunction in early stages of neurological disorders, offering hope for patients suffering from memory loss, cognitive deficits, and impaired motor function.
Generated from the website